Cancer Medicine Publishes its Second Issue

Cancer MedicineCancer Medicine has now published Issue 1:2.

The journal brings together articles on a range of oncology specialties, covering cancer biology, clinical cancer research and cancer prevention, with authors from across the globe.

We hope that you enjoy the exciting new content Issue 1:2 has to offer! Below are some top articles which Editor-in-Chief Prof. Qingyi Wei has highlighted from the issue.

purple_lock_open Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1
Leticia M. Nogueira, Jackie A. Lavigne, Gadisetti V. R. Chandramouli, Huaitian Lui, J. Carl Barrett and Stephen D. Hursting

Summary: We compared the effects of different levels of calorie restriction (CR), with and without infusion of IGF-1 (a potential mediator of the anticancer effects of CR), on hepatic and mammary gland gene expression and mammary tumor progression. We found (1) several genes and pathways, particularly those associated with macronutrient and steroid hormone metabolism, are associated with the anticancer effects of moderate (30%) CR; (2) mild CR (20%) has little effect on gene expression relative to control, whereas 40% CR modulates metabolic pathways as well as a broad panel of stress-related and DNA damage-related genes, suggesting this level of CR is too severe; and (3) reduced IGF-1 levels can account, at least in part, for many of the effects of CR on metabolism-related gene expression and mammary tumor burden.

purple_lock_openEGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
Roshan James, Siddharth Vishwakarma, Indira V. Chivukula, Chetana Basavaraj, Ramakrishnan Melarkode, Enrique Montero and Pradip Nair

Summary: Nimotuzumab, an antibody with intermediate affinity and thereby limited skin toxicity combines synergistically with Sirolimus to inhibit the proliferation of even low EGFR-expressing cells. These molecules affect the complementary signaling hubs of EGFR and mTOR. The mode of action of the drugs is investigated in vitro and in vivo. The results would suggest the feasibility of this drug combination at doses lower than the current therapeutic doses, in cancer patients expressing EGFR differently.

Cancer Medicine is a peer reviewed, interdisciplinary journal providing rapid publication of cutting-edge research from global biomedical researchers across the cancer sciences.

Submit your paper here >  Sign-up for eToC alerts here >